Trade

with

ACADIA Pharmaceuticals Inc
(NASDAQ: ACAD)
AdChoices
26.06
+0.77
+3.04%
After Hours :
26.06
0.00
0.00%

Open

26.00

Previous Close

25.29

Volume (Avg)

1.59M (1.19M)

Day's Range

25.70-26.87

52Wk Range

15.64-32.00

Market Cap.

2.59B

Dividend Rate ( Yield )

-

Beta

2.88

Shares Outstanding

99.44M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.14M

    • Net Income

    • -37.95M

    • Market Cap.

    • 2.59B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -18,527.46

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.88

    • Forward P/E

    • -

    • Price/Sales

    • 10,000.00

    • Price/Book Value

    • 7.40

    • Price/Cash flow

    • -42.92

      • EBITDA

      • -38.22M

      • Return on Capital %

      • -21.92

      • Return on Equity %

      • -23.35

      • Return on Assets %

      • -21.92

      • Book Value/Share

      • 3.52

      • Shares Outstanding

      • 99.44M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 23.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • 0.51

        • Cashflow Estimate

        • 0.77

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -93.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -6.36

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -18,527.46

            • 39.38

            • Net Profit Margin

            • -18,527.46

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,102.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 38.43

              • 2.92

              • Quick Ratio

              • 38.10

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.03

              • 2.21

              • Book Value/Share

              • 3.52

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -35.09

                • 188.68

                • P/E Ratio 5-Year High

                • -48.04

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.98

                • 124.82

                • Price/Sales Ratio

                • 5,000.00

                • 8.72

                • Price/Book Value

                • 6.64

                • 7.95

                • Price/Cash Flow Ratio

                • -42.92

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -23.35

                    (-43.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -21.92

                    (-32.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -23.35

                    (-43.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -38.30M
                  Operating Margin
                  -3,344.72
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -42.92
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  83.58%

                  Mutual Fund Ownership

                  42.52%

                  Float

                  63.03%

                  5% / Insider Ownership

                  0.33%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    4,456,364

                  • 0.18

                  • 4.48

                  • Fidelity® Growth Company Fund

                  •  

                    2,795,397

                  • 1.42

                  • 2.81

                  • T. Rowe Price Health Sciences Fund

                  •  

                    2,141,800

                  • 179.46

                  • 2.16

                  • T. Rowe Price New Horizons Fund

                  •  

                    1,786,800

                  • 149.38

                  • 1.80

                  • Franklin Biotechnology Discovery

                  •  

                    1,443,000

                  • 82.66

                  • 1.46

                  • Vanguard Small Cap Index

                  •  

                    1,381,813

                  • 0.11

                  • 1.39

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,298,480

                  • 0.18

                  • 1.31

                  • iShares Nasdaq Biotechnology

                  •  

                    1,288,636

                  • 0.24

                  • 1.32

                  • iShares Russell 2000 (AU)

                  •  

                    1,248,407

                  • 3.57

                  • 1.28

                  • Fidelity® Puritan® Fund

                  •  

                    1,207,500

                  • 0.00

                  • 1.21

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    20,481,442

                  • 0.00%

                  • 20.63

                  • Fidelity Management and Research Company

                  •  

                    14,843,448

                  • +1.49%

                  • 14.95

                  • T. Rowe Price Associates, Inc.

                  •  

                    5,962,463

                  • +114.21%

                  • 6.00

                  • Vanguard Group, Inc.

                  •  

                    4,829,652

                  • +0.83%

                  • 4.86

                  • Viking Global Investors LP

                  •  

                    4,757,878

                  • +32.22%

                  • 4.79

                  • Jennison Associates LLC

                  •  

                    3,053,525

                  • +0.13%

                  • 3.08

                  • BlackRock Fund Advisors

                  •  

                    2,935,943

                  • -4.29%

                  • 2.96

                  • Westfield Capital Management Company, LP

                  •  

                    2,308,261

                  • -1.67%

                  • 2.32

                  • Franklin Advisers, Inc.

                  •  

                    2,124,600

                  • +70.68%

                  • 2.14

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small...more molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company h...moreas completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.lessless

                  Key People

                  Dr. Uli Hacksell,PhD

                  CEO/Director/President

                  Dr. Leslie L. Iversen,PhD

                  Chairman of the Board/Director

                  Mr. Stephen R. Davis

                  CFO/Chief Accounting Officer/Executive VP/Other Executive Officer

                  Dr. Roger M. Mills,M.D.

                  Chief Medical Officer/Executive VP, Divisional

                  Terrence O. Moore

                  Executive VP/Other Executive Officer

                  • ACADIA Pharmaceuticals Inc

                  • 11085 Torreyana Road

                  • San Diego, CA 92121

                  • USA.Map

                  • Phone: +1 858 558-2871

                  • Fax: +1 858 558-2872

                  • acadia-pharm.com

                  Incorporated

                  1993

                  Employees

                  48

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: